An interventional study of Device treatment in Erectile Dysfunction, sponsored by InMode MD Ltd.. Recruiting at 2 sites in United States. Open to male participants aged 40 Years to 80 Years. Per ClinicalTrials.gov, last updated 2024-03-07.
Sponsored by InMode MD Ltd. (part of InMode Ltd.) · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 180 studies in Erectile Dysfunction with a site in United States — 26 open to participants now, 31 under way, 3 of them phase 3. Erectile Dysfunction · United States.
Among the 180 studies in Erectile Dysfunction with a site in United States, this one is the 121st largest by planned enrollment of the 164 interventional ones that give a count, is one of 12 that started in 2023, is one of 62 with no phase, reaches primary completion later than 1 of the 30 other live ones, and was the 160th registered.
702 studies on the registry are indexed under Erectile Dysfunction; 125 are open to participants now.
Browse Erectile Dysfunction studies →26 of the 180 studies in Erectile Dysfunction with a site in United States are open now. Recruiting first, the newest first:
Duke University · Sites in United States
Ages 18+ · Men only
The Methodist Hospital Research Institute · Sites in United States
Ages 40–70 · Men only
Rigicon, Inc. · Sites in United States
Ages 22+ · Men only
J. Peter Rubin, MD · Sites in United States
Ages 18+ · Men only
University of California, Irvine · Sites in United States
Ages 18+ · Men only
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 78 Erectile Dysfunction studies recruiting now, 31 (40%) set no upper age limit and 34 (44%) stop at 75 or younger; 2 take children under 18; 7 take healthy volunteers.
This study: 40 Years to 80 Years · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
180 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 25 · Phase 2 26 · Phase 3 32 · Phase 4 25
First in 1988; this study’s year is marked. 12 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 20 is below the median of 70 across 551 interventional studies indexed under Erectile Dysfunction.
Median enrollment 75 across the 164 interventional studies, 93 across the 16 observational. Of the 128 that completed or were terminated, 51 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
93 of 180 have an industry lead sponsor. The 10 most frequent:
This study is registered under InMode MD Ltd., one of the names counted as InMode Ltd.. Under that name alone:
InMode MD Ltd. is the lead sponsor of 25 studies on the registry; 4 are open to participants now.
Of its 18 completed or terminated interventional studies of FDA-regulated products, 8 (44%) have results posted.
InMode Ltd. has 1 study filed under Erectile Dysfunction — fewer than ten, so there is no comparison to draw.
14 of the studies in Erectile Dysfunction with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03701581Phase 3John Elfar4-aminopyridine Treatment for Nerve Injury | 2027-07 |
| NCT06945315Phase 3Icahn School of Medicine at Mount SinaiSAFE Nerve Sparing Guided by Micro-ultrasound (MUS) | 2027-07-14 |
| NCT06065436Mayo ClinicConcurrent Low Intensity Shockwave Therapy on Collagenase Clostridium Histolyticum for Peyronie's Disease | 2026-12 |
| NCT05868668The Cleveland ClinicEfficacy of Low-intensity Shockwave vs Radial Wave for Treatment of Erectile Dysfunction and Pelvic Pain | 2026-12 |
| NCT02706561Memorial Sloan Kettering Cancer CenterHelping Men Adhere to Sexual Rehabilitation Following Prostate Cancer Surgery | 2026-12 |
Add all 14 to your calendar (.ics) → With an account.
Among the 180 studies in Erectile Dysfunction with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this prospective pilot study is to learn about the Safety and Efficacy of Radiofrequency (RF) for the Treatment of Erectile Dysfunction. This research study is trying to determine if RF therapy is safe and effective in patients with symptoms of erectile dysfunction (ED).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Participation in another study within 30 days prior to screening.
-
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Eligible subjects will receive 6 weekly treatments with the Forma Applicator according to the study protocol and will return for two follow up visits 1- and 3-months post treatment. Two further telephone feedback checks will be carried out 6 months and 12 months following the last treatment visit.
Device: Device treatment
20 heterosexual males clinically diagnosed with Erectile Dysfunction will receive 6 weekly treatments with the Forma Applicator according to the study protocol and will return for two follow up visits 1- and 3-months post treatment. Two further telephone feedback checks will be carried out 6 months and 12 months following the last treatment visit
Change in ED symptoms, following the RF treatment
Change in ED symptoms, following the RF treatment measured by THE INTERNATIONAL INDEX OF ERECTILE FUNCTION - ERECTILE FUNCTION (IIEF-EF) questionnaire score. The IIEF-5 score is the sum of the ordinal responses to the 5 items.(1 to 5 ) 22-25: No erectile dysfunction 17-21: Mild erectile dysfunction 12-16: Mild to moderate erectile dysfunction 8-11: Moderate erectile dysfunction 5-7: Severe erectile dysfunction
Time frame: 3 months
Change in sexual activity leading to optimal penetration
Change in sexual activity leading to optimal penetration measured by SEP- Sexual Encounter Profile questionnaire. The SEP questionnaire consists of 5 items addressing the sexual events and subject experiences when attempting intercourse. Efficacy of RF treatment evaluated using the change in percentage of "yes" responses to Sexual Encounter Profile (SEP) Questions 2 and 3
Time frame: 3 months
Evaluate efficacy of the RF treatment for erectile function
Proportion of subject responses to Global Assessment Questionnaire (GAQ) consisting of 2 questions (Yes or No): Question 1 'Has the treatment you have been taking improved your erectile function?' and if necessary, Question 2 'If yes, has the treatment improved your ability to engage in sexual activity?'.
Time frame: 3 months
Evaluate efficacy of the RF treatment for erectile function
Proportion of subject responses to Global Assessment Questionnaire (GAQ) consisting of 2 questions (Yes or No): Question 1 'Has the treatment you have been taking improved your erectile function?' and if necessary, Question 2 'If yes, has the treatment improved your ability to engage in sexual activity?'.
Time frame: 6 months
Evaluate efficacy of the RF treatment for erectile function
Proportion of subject responses to Global Assessment Questionnaire (GAQ) consisting of 2 questions (Yes or No): Question 1 'Has the treatment you have been taking improved your erectile function?' and if necessary, Question 2 'If yes, has the treatment improved your ability to engage in sexual activity?'.
Time frame: 12 months
Evaluate efficacy of the RF treatment for hardness of erection
To assess the effectiveness of RF treatment for erectile dysfunction with the Erectile Hardness Score (EHS) questionnaire The Erection Hardness Score is a self-reported tool that measures the hardness of an erection. It involves a scale report from 0 to 4, 4 being the best quality of erection.
Time frame: 3 months
Measuring pain level during the procedure
NPRS is a unidimensional measure of pain intensity in adults. The 11-point numeric scale ranges from '0' representing one pain extreme (e.g. "no pain") to '10' representing the other pain extreme (e.g. "pain as bad as you can imagine" or "worst pain imaginable").
Time frame: During the procedure
Plan to share: No
No publications or documents are linked to this record.
Started Jun 2023 (actual). Primary completion is estimated for May 2024, 11 months after the start.
Of 137 interventional studies with no phase under Erectile Dysfunction, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 52. This study's planned 11 months is below that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.